Company intelligence / Profile preview

Amyl Therapeutics

Ownership: Private
Employees: ~10
Development stage: Preclinical

Overview

The company is developing novel molecules that conformationally bind to the amyloid fold of toxic protein aggregates. Their lead candidate is expected to begin Phase I trials in 2025 for amyloidosis, with preclinical studies ending in the coming months. The company claims its technology can target all amyloid fibrils, offering an advantage over classical monoclonal antibodies.

Therapeutic areas: HematologyNeurology
Modalities: Pan-Amyloid Immunotherapy
Industry: Biotech

Drug pipeline

11 assets

AMYL-00z

Preclinical

10 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Amyl Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Amyl Therapeutics.

Explore the full profile